Cefuroxime Sodium for Injection

This product is a second-generation cephalosporin antibiotic. Its antibacterial activity against Gram-positive cocci is similar to or slightly inferior to that of the first-generation cephalosporins, but it is quite stable against beta-lactamase produced by Staphylococci and Gram-negative bacilli. Methicillin-resistant Staphylococci, Enterococci and Listeria are resistant, while other positive cocci (including anaerobic cocci) are sensitive to this product. Its antibacterial activity against Staphylococcus aureus is poorer than that of cefazolin, and 1-2 mg/L can inhibit all Staphylococcus aureus that are sensitive and resistant to penicillin, respectively. It has strong antibacterial activity against Haemophilus influenzae, and Escherichia coli, Proteus mirabilis, etc. may be sensitive to this product; indole-positive Proteus, Citrobacter and Acinetobacter are poorly sensitive to this product, most Serratia are resistant, and Pseudomonas aeruginosa, Campylobacter and Bacteroides fragilis are resistant to this product. Its mechanism of action is to bind to penicillin-binding proteins (PBPs) on the bacterial cell membrane, acylate the transpeptidase, inhibit the synthesis of the bacterial septum and cell wall, affect the cross-linking of the cell wall mucopeptide components, inhibit cell division and growth, elongate the bacterial morphology, and finally dissolve and die.

The main ingredient of this product is cefuroxime sodium, and its chemical name is: (6R, 7R)-7-[2-furanyl(methoxyimino)acetylamino]-3-carbamoyloxymethyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt.

This product is white to slightly yellow powder or crystalline powder.

Used for the following diseases caused by sensitive bacteria: 1. Respiratory tract infections: acute and chronic bronchitis, infectious bronchiectasis, bacterial pneumonia, lung abscess and postoperative chest infection. 2. Ear, nose and throat infections: sinusitis, tonsillitis, pharyngitis. 3. Urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. 4. Skin and soft tissue infections: cellulitis, erysipelas, peritonitis and traumatic infection. 5. Bone and joint infections: osteomyelitis and septic arthritis. 6. Obstetric and gynecological infections: pelvic inflammatory disease. 7. Gonorrhea: especially suitable for those who are not suitable for penicillin treatment. 8. Other infections: including sepsis and meningitis; abdominal pelvic and orthopedic surgery; heart, lung, esophageal and vascular surgery; prevention of infection during total joint replacement surgery.

Intramuscular injection, intravenous injection or intravenous drip. 1. Intramuscular injection: 0.25g of Cefuroxime Sodium for Injection is added to 1ml of water for injection or 0.75g of Cefuroxime Sodium for Injection is added to 3ml of water for injection, and gently shaken to make an opaque suspension. 2. Intravenous injection: 0.25g of Cefuroxime Sodium for Injection is added to at least 2ml of water for injection or 0.75g of Cefuroxime Sodium for Injection is added to at least 6ml of water for injection to dissolve into a yellow clear solution. 3. Intravenous drip: 1.5g of Cefuroxime Sodium for Injection can be dissolved in 50ml of water for injection or combined with most commonly used intravenous injection solutions (except aminoglycosides). General or moderate infection: 0.75g once, 3 times a day, intramuscular or intravenous injection. Severe infection: Double the dose, 1.5g once, 3 times a day, intravenous drip for 20 to 30 minutes. Infants and children are given 30 to 100mg/kg per day according to their body weight, divided into 3 to 4 doses.

1 Occasionally, skin rash and elevated serum aminotransferase may occur, but the symptoms disappear after discontinuation of the drug. 2 There is a cross-allergic reaction with penicillin. 3 According to literature reports, long-term use of this product can lead to the proliferation of non-sensitive bacteria and gastrointestinal disorders, including pseudomembranous colitis, which rarely occurs in the middle and late stages of treatment. 4 Rare transient decreases in hemoglobin concentration, eosinophilia, and leukocytopenia and neutrophilia may occur, but the symptoms disappear after discontinuation of the drug. 5 When injected intramuscularly, there will be temporary pain at the injection site, especially when the dose is large.

This product is contraindicated for patients who are allergic to cephalosporins.

1. This product is contraindicated with the following drugs: amikacin sulfate, gentamicin, kanamycin, tobramycin, neomycin, chlortetracycline hydrochloride, tetracycline hydrochloride, oxytetracycline hydrochloride, colistin sodium methanesulfonate, polymyxin B sulfate, erythromycin gluconate, erythromycin lactobionate, lincomycin, sulfisoxazole, aminophylline, soluble barbiturates, calcium chloride, calcium glucoheptonate, diphenhydramine hydrochloride and other antihistamines, lidocaine, norepinephrine, metaraminol, methylphenidate, succinylcholine, etc. Occasionally, it may also be contraindicated with the following drugs: penicillin, methicillin, hydrocortisone succinate, phenytoin sodium, prochlorperazine, vitamin B group and vitamin C, hydrolyzed protein. 2. The stability in sodium bicarbonate solution is worse than in other solutions. 3. This product cannot be administered in the same container with aminoglycoside antibiotics. Precipitation may occur when mixed with vancomycin. 4 When this product is used in combination with aminoglycoside antibiotics or strong diuretics such as furosemide, renal function must be closely monitored to avoid the occurrence of renal damage.

Keep in a cool place, sealed and protected from light. Validity period: 24 months

2.25g

Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Guangzhou Baiyunshan Pharmaceutical General

• Founded in:

  1973-07-01

• Address:

  No. 88, Yunxiang Road, Tonghe Street, Baiyun District, Guangzhou

• Tax NO.:

  91440101714253245D

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view